520 E 70th St# StarrNew York, NY 10021
Fax+1 212-746-3305
Overview of Dr. Leonard
Dr. Leonard attended Johns Hopkins as an undergraduate and went on to receive his medical degree at the University of Virginia School of Medicine. After completing his residency in medicine at the NewYork-Presbyterian Weill Cornell Medical Center and Memorial Sloan Kettering Cancer Center, he did a fellowship in hematology and oncology at Cornell and served as the chief medical resident at the NewYork-Presbyterian Weill Cornell Medical Center.
He has contributed extensively to the field of lymphoma and related blood cancers through his research on innovative treatment approaches, with his work featured in numerous medical journals. He has held editorial board positions for prominent publications, including Blood and the Journal of Clinical Oncology. He serves as chair of the Lymphoma Committee for the Alliance for Clinical Trials in Oncology, a major multicenter cooperative group integral to the National Cancer Institute’s National Clinical Trials Network. Dr. Leonard is a past elected member of the American Board of Internal Medicine’s hematology subspecialty board and is also an elected member of the American Society of Clinical Investigation. His leadership roles extend to having chaired the Scientific Advisory Board and current service on the board of the Lymphoma Research Foundation, as well as being a board member of the Leukemia & Lymphoma Society’s New York City chapter. In recognition of his compassionate patient care, he was honored with the Miriam G. Wallach Award for Excellence in Humanistic Medical Care by NewYork-Presbyterian/Weill Cornell Medicine in 2017.
Education & Training
New York Presbyterian Hospital (Cornell Campus)Fellowship, Hematology and Medical Oncology, 1993 - 1996- New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 1990 - 1993
University of Virginia School of MedicineClass of 1990
Certifications & Licensure
NY State Medical License 1991 - 2026
NJ State Medical License 1975 - 2025
American Board of Internal Medicine Hematology- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Miriam G. Wallach Award for Excellence in Humanistic Medical Care NewYork-Presbyterian/Weill Cornell Medicine, 2017
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2012-2014, 2016-2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2012-2014, 2016-2017
Clinical Trials
- A Phase I Study of Immunotherapy With hA20 Administered Once Weekly for 4 Consecutive Weeks in Patients With CD20+ Non-Hodgkin's Lymphoma Start of enrollment: 2004 Feb 01
- Rituximab and/or Lenalidomide in Treating Patients With Follicular Non-Hodgkin's Lymphoma That is Not Refractory to Rituximab Start of enrollment: 2006 Mar 01
- Phase I Open-Label Dose Finding Study of SGN-35 for CD30 Positive Hematologic Malignancies Start of enrollment: 2006 Nov 01
Publications & Presentations
PubMed
- 1 citationsComparative infection risk in CAR T vs bispecific antibodies in B-cell lymphoma: a systematic review and meta-analysis.Herman van Besien, Neela Easwar, Michelle Demetres, Michelle Pasciolla, Tsiporah Shore
Blood Advances. 2025-12-09 - Outcomes of relapsed/refractory peripheral T-cell lymphoma in the modern era: impact of stem cell transplant and novel agents.Seda S Tolu, Caitlin Gribbin, Zhengming Chen, Madhav R Seshadri, Evelyn Orlando
Leukemia & Lymphoma. 2025-12-01 - Unstacking the deck in follicular lymphoma clinical trials.Samuel Yamshon, John P Leonard
Journal of the National Cancer Institute. 2025-11-01
Journal Articles
- Five-Year Follow-up of Lenalidomide plus Rituximab as Initial Treatment for Mantle Cell LymphomaJia Ruan, Jakub Svoboda, John P Leonard, Sonali M Smith, Morton Coleman, Richard R Furman, Blood
- CALBG 50604: Risk-Adapted Treatment of Non-Bulky Early Stage Hodgkin Lymphoma Based on Interim PETDavid J Straus, Heiko Schoder, Bruce D Cheson, John C Grecula, Lale Kostakoglu, Eric D Hsi, Leslie L Popplewell, John P Leonard, Craig H Moskowitz, Brad S Kahl, Jonath..., Blood
Abstracts/Posters
- Consensus and Divergence in Practice Patterns Among Experts and Community Healthcare Providers for the Treatment of Patients with Mantle Cell LymphomaJohn P. Leonard, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Subgroup Analyses of Elderly Patients Aged _ 70 Years in AUGMENT: A Phase III Randomized Study of Lenalidomide Plus Rituximab (R2) vs Rituximab Plus Placebo (R-Placebo...John P. Leonard, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Intraclonal Heterogeneity Caused By Activation-Induced Cytidine Deaminase Is Not a Prognostic Biomarker in Untreated Advanced Stage Follicular Lymphoma: An Analysis of...John P. Leonard, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Lectures
- Realizing the Promise of Novel Therapeutics in NHL: A MasterClass and Tumor Board on Clinical Decision-Making in FL, MCL, and DLBCL61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Hodgkin Lymphoma: Genes to Microenvironment to Immunotherapy61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Follicular Lymphoma: Have We Made Progress?60th American Society of Hematology Annual Meeting - 12/3/2018
Press Mentions
“Substantial” Reduction in Risk for Progression or Death in RR/FL with Epcoritamab Plus R2December 8th, 2025- Cancer Progression Illuminated by New Multi-Omics ToolOctober 10th, 2025
- NYU Langone Health Brings on Two Acclaimed Cancer Experts to Lead Ambitious New Gastrointestinal Cancer CenterSeptember 5th, 2025
Grant Support
- Generation Of Kinase-Resistant NMDA Receptors By Gene-Targeting In The MouseNational Institute Of Neurological Disorders And Stroke2008–2009
- Novel Monoclonal Antibody Therapies For LymphomaNational Center For Research Resources2001–2005
- PH. II Trial/ Depsipeptide In Cutaneous T-Cell Lymphoma/ Relapsed PeripheralNational Center For Research Resources2004
- Evaluation Of Functional Status, Quality Of Life, /Outcome /Older Lymphoma PTSNational Center For Research Resources2004
- NMDA Receptor Modulation By Kinases--Molecular StudiesNational Institute Of Neurological Disorders And Stroke1998
Committees
- Chair, Lymphoma Committee for Clinical Trials
Insurance Accepted
- Aetna Choice POS II
Aetna HMO
BCBS Blue Card PPO
BCBS California PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Empire BCBS HMO
Empire BCBS PPOGHI PPO
Great West PPO
HIP of New York - Select PPO
Humana ChoiceCare Network PPO
MVP Healthcare PPO
Oxford Health Freedom
Oxford Health Liberty
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO - Please verify your coverage with the provider's office directly when scheduling an appointment
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
